We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
FDA actions.
- Abstract
The article reports on the approval of the Food and Drug Administration in the U.S. to several drugs and drug manufacturers. It mentions that it approved the oral factor Xa inhibitor rivaroxaban for patients who undergone knee or hip replacement. It adds that the new antiplatelet drug ticagrelor was also approved for patients with acute coronary syndrome including unstable angina and manufacturers including Sanofi Pasteur SA was permitted to market the first flu vaccine Fluzone Intradermal.
- Subjects
DRUG approval; UNITED States. Food &; Drug Administration; TOTAL hip replacement; PLATELET aggregation inhibitors; ACUTE coronary syndrome; SANOFI Pasteur SA; PATIENTS
- Publication
OB/GYN Clinical Alert, 2011, p2
- ISSN
0743-8354
- Publication type
Article